CoChat

Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors

Open access
Mahiat, Cédric, Bihin, Benoît, Duplaquet, Fabrice, Stanciu Pop, Claudia, Dupont, Michael, Vander Borght, Thierry, Rondelet, Benoît, Vanderick, Jean, André, Bénédicte, Pirard, Lionel, Ocak, Sebahat · 2023 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

Biomarkers of systemic inflammation/nutritional status have been associated with outcomes in advanced-stage non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However, most of them were not tested in cohorts of patients treated with ICIs in combination with chemotherapy (CT) (ICI + CT) or with CT alone, making it impossible to discriminate a predictive from a prognostic effect. We conducted a single-center retrospective study to search for associations between various baseline biomarkers/scores that reflected the systemic inflammation/nutritional status (Lung Immune Prognostic Index, Modified Lung Immune Prognostic Index, Scottish Inflammatory Prognostic Score, Advanced Lung Cancer Inflammation Index, EPSILoN, Prognostic Nutritional Index, Systemic Immune-Inflammation Index, Gustave Roussy Immune Score, Royal Marsden Hospital Prognostic Score, Lung Immuno-oncology Prognostic Score 3, Lung Immuno-oncology Prognostic Score 4, score published by Holtzman et al., and Glasgow Prognostic Score) and outcomes in metastatic NSCLC treated in a first-line setting either with ICI in monotherapy (cohort 1; n = 75), ICI + CT (cohort 2; n = 56), or CT alone (cohort 3; n = 221). In the three cohorts, the biomarkers/scores were moderately associated with overall survival (OS) and progression-free survival (PFS). Their prognostic performance was relatively poor, with a maximum c-index of 0.66. None of them was specific to ICIs and could help to choose the best treatment modality. The systemic inflammation/nutritional status, associated with outcomes independently of the treatment, is therefore prognostic but not predictive in metastatic NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms24043618

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The Kaplan–Meier curves of overall survival and progression-free survival in the three cohorts of patients, treated with ICI + CT, ICI in monotherapy, or CT alone. Abbreviations: CT—chemotherapy, ICI—immune checkpoint inhibitor, and ICI + CT—ICI in combination with CT.
Figure 1 The Kaplan–Meier curves of overall survival and progression-free survival in the three cohorts of patients, treated with ICI + CT, ICI in monotherapy, or CT alone. Abbreviations: CT—chemotherapy, ICI—immune checkpoint inhibitor, and ICI + CT—ICI in combination with CT.CC BY · PubMed Central
Figure 2 One-year overall survival (OS) and six-month progression-free survival (PFS) in the three cohorts, according to the scores based on biomarkers of systemic inflammation/nutritional status, analyzed as binary variables (high or low level). The numbers indicated in the squares represent the Kaplan–Meier estimation of the one-year OS or the six-month PFS. Abbreviations: ALI—Advanced Lung Cancer Inflammation Index [28], CT—chemotherapy alone, EPSILoN [32], GPS—Glasgow Prognostic Score [46], GRIm—Gustave Roussy Immune Score [33], Holtzman—score described by Holtzman et al. [36], ICI—ICI in monotherapy, ICI + CT—ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified Lung Immune Prognostic Index [30], PNI—Prognostic Nutritional Index [43], RMH—Royal Marsden Hospital Prognostic Score [45], SII—Systemic Immune-Inflammation Index [44], and SIPS—Scottish Inflammatory Prognostic Score [31].
Figure 2 One-year overall survival (OS) and six-month progression-free survival (PFS) in the three cohorts, according to the scores based on biomarkers of systemic inflammation/nutritional status, analyzed as binary variables (high or low level). The numbers indicated in the squares represent the Kaplan–Meier estimation of the one-year OS or the six-month PFS. Abbreviations: ALI—Advanced Lung Cancer Inflammation Index [28], CT—chemotherapy alone, EPSILoN [32], GPS—Glasgow Prognostic Score [46], GRIm—Gustave Roussy Immune Score [33], Holtzman—score described by Holtzman et al. [36], ICI—ICI in monotherapy, ICI + CT—ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified Lung Immune Prognostic Index [30], PNI—Prognostic Nutritional Index [43], RMH—Royal Marsden Hospital Prognostic Score [45], SII—Systemic Immune-Inflammation Index [44], and SIPS—Scottish Inflammatory Prognostic Score [31].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 23

Metadata

Authors
Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., & Ocak, S.
Affiliations
  • UCLouvain (BE)
  • CHU Dinant Godinne UCL Namur (BE)
  • Pathology Department, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
  • Radiology Division, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
  • Nuclear Medicine Division, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
  • Thoracic Surgery Department, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
Corresponding author
Ocak, Sebahat
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-02-10
Volume
24
Issue
4
Pages
3618
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4320493683
Cited by
23
References
73
Citations by year
2026: 8 · 2025: 6 · 2024: 6 · 2023: 3
FWCI
2.79
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Libraries (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
metastatic non-small cell lung cancer, immune checkpoint inhibitors, systemic inflammation, nutritional status, prognostic factors, prognostic score, first-line therapy, chemotherapy, overall survival, progression-free survival, immune-related adverse events
MeSH terms
Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Inflammation, Lung Neoplasms, Nutritional Status, Prognosis, Retrospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.